Pneumothorax without CC/MCC DRG Reimbursement Guide

DRG 201 pertains to inpatient stays for pneumothorax without Complication or Comorbidity or Major Complication or Comorbidity and defines a lower-severity payment category for these cases. Proper assignment is important because it determines the bundled Medicare payment level for the hospital stay and reflects the expected resource use.

DRG 201 Overview

DRG 201 covers inpatient admissions for pneumothorax without a Complication or Comorbidity or Major Complication or Comorbidity. This category includes primary spontaneous pneumothorax and traumatic or iatrogenic pneumothorax cases that do not carry additional coded complications or comorbid conditions. It matters for Medicare payment because the Diagnosis-Related Group assignment determines the bundled payment for the hospital stay and influences resource intensity and reimbursement. Accurate coding and documentation of concurrent conditions affect whether an admission remains in this lower-severity payment group or moves to a higher-paying group.

Acute intervention trials evaluating minimally invasive procedures (e.g., needle aspiration vs small-bore chest tube) for initial management of primary or secondary spontaneous pneumothorax in hospitalized adults. These studies enroll patients presenting with symptomatic pneumothorax who require inpatient intervention and compare procedural success, time to lung re-expansion, complication rates, and length of stay; outcomes inform best practices for emergency and inpatient procedural choices. Results are highly relevant to providers deciding initial invasive management and to payers and hospitals because differences in procedure success and complication rates directly impact resource utilization and reimbursement under this DRG.
Comparative effectiveness studies of inpatient management strategies for pneumothorax with comorbid pulmonary disease versus otherwise healthy patients, assessing conservative observation, tube thoracostomy, and surgical interventions (e.g., VATS pleurodesis). These trials or prospective cohorts stratify by underlying lung disease (such as COPD, cystic fibrosis, or interstitial lung disease), measuring recurrence, ventilator dependence, ICU transfer, and in-hospital mortality to determine which approaches minimize complications in high-risk subgroups. Findings guide clinicians on tailoring interventions by risk profile and help payers identify subpopulations with higher expected costs and readmission risk for case-mix adjustments and care pathway development.
Post-discharge outcomes and care coordination studies focusing on readmission reduction, outpatient follow-up timing, and rehabilitation after inpatient treatment for pneumothorax. These pragmatic trials or quality-improvement studies test bundled discharge pathways, scheduled imaging follow-up, and patient education to reduce early recurrence and emergency readmissions over 30–90 days, tracking patient-centered outcomes and total episodic cost. This research is important to hospitals and payers because improved discharge processes can lower readmission rates and downstream costs for cases billed under this DRG, while ensuring safe transitions for patients at risk of recurrence.

Acute intervention trials evaluating minimally invasive procedures (e.g., needle aspiration vs small-bore chest tube) for initial management of primary or secondary spontaneous pneumothorax in hospitalized adults. These studies enroll patients presenting with symptomatic pneumothorax who require inpatient intervention and compare procedural success, time to lung re-expansion, complication rates, and length of stay; outcomes inform best practices for emergency and inpatient procedural choices. Results are highly relevant to providers deciding initial invasive management and to payers and hospitals because differences in procedure success and complication rates directly impact resource utilization and reimbursement under this DRG.
Comparative effectiveness studies of inpatient management strategies for pneumothorax with comorbid pulmonary disease versus otherwise healthy patients, assessing conservative observation, tube thoracostomy, and surgical interventions (e.g., VATS pleurodesis). These trials or prospective cohorts stratify by underlying lung disease (such as COPD, cystic fibrosis, or interstitial lung disease), measuring recurrence, ventilator dependence, ICU transfer, and in-hospital mortality to determine which approaches minimize complications in high-risk subgroups. Findings guide clinicians on tailoring interventions by risk profile and help payers identify subpopulations with higher expected costs and readmission risk for case-mix adjustments and care pathway development.
Post-discharge outcomes and care coordination studies focusing on readmission reduction, outpatient follow-up timing, and rehabilitation after inpatient treatment for pneumothorax. These pragmatic trials or quality-improvement studies test bundled discharge pathways, scheduled imaging follow-up, and patient education to reduce early recurrence and emergency readmissions over 30–90 days, tracking patient-centered outcomes and total episodic cost. This research is important to hospitals and payers because improved discharge processes can lower readmission rates and downstream costs for cases billed under this DRG, while ensuring safe transitions for patients at risk of recurrence.

OpenPayer

Summary & Overview

Pneumothorax without CC/MCC: Inpatient Reimbursement Overview

DRG 201 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes